 Nikhil Meena
Concepts (233)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 11 | 2025 | 597 | 2.930 |
Why?
| | Vasopressins | 4 | 2019 | 39 | 2.260 |
Why?
| | Shock, Septic | 5 | 2023 | 79 | 2.250 |
Why?
| | Vasoconstrictor Agents | 4 | 2019 | 83 | 2.180 |
Why?
| | Biopsy, Fine-Needle | 6 | 2021 | 108 | 1.930 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 5 | 2023 | 46 | 1.660 |
Why?
| | Norepinephrine | 3 | 2018 | 114 | 1.650 |
Why?
| | Bronchoscopy | 6 | 2025 | 74 | 1.620 |
Why?
| | Dyspnea | 5 | 2022 | 75 | 1.280 |
Why?
| | Pleural Effusion | 3 | 2019 | 38 | 1.180 |
Why?
| | Pleural Effusion, Malignant | 2 | 2017 | 20 | 1.020 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2019 | 326 | 1.010 |
Why?
| | Pneumonia | 2 | 2025 | 124 | 0.990 |
Why?
| | Intensive Care Units | 5 | 2019 | 228 | 0.940 |
Why?
| | Aged | 21 | 2025 | 9738 | 0.890 |
Why?
| | Humans | 48 | 2025 | 50419 | 0.880 |
Why?
| | Male | 33 | 2025 | 25866 | 0.880 |
Why?
| | Sensitivity and Specificity | 3 | 2025 | 855 | 0.870 |
Why?
| | Retrospective Studies | 19 | 2025 | 6274 | 0.840 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2025 | 27 | 0.830 |
Why?
| | Obesity | 2 | 2025 | 1123 | 0.830 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2023 | 106 | 0.810 |
Why?
| | Middle Aged | 22 | 2025 | 12579 | 0.790 |
Why?
| | Body Mass Index | 1 | 2025 | 674 | 0.740 |
Why?
| | Female | 30 | 2025 | 27053 | 0.740 |
Why?
| | Mycobacterium tuberculosis | 1 | 2023 | 266 | 0.740 |
Why?
| | Tracheostomy | 2 | 2020 | 71 | 0.740 |
Why?
| | Ticlopidine | 3 | 2016 | 53 | 0.710 |
Why?
| | Nausea | 1 | 2021 | 46 | 0.700 |
Why?
| | Adult | 19 | 2025 | 13561 | 0.700 |
Why?
| | Pleurodesis | 2 | 2017 | 8 | 0.700 |
Why?
| | Diarrhea | 1 | 2021 | 91 | 0.690 |
Why?
| | Vomiting | 1 | 2021 | 71 | 0.680 |
Why?
| | Thoracoscopy | 2 | 2019 | 17 | 0.670 |
Why?
| | Cough | 3 | 2022 | 56 | 0.660 |
Why?
| | Esophagus | 2 | 2017 | 81 | 0.650 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2016 | 174 | 0.650 |
Why?
| | Time Factors | 4 | 2019 | 2933 | 0.640 |
Why?
| | Bronchoscopes | 2 | 2016 | 9 | 0.620 |
Why?
| | Delayed Diagnosis | 1 | 2019 | 24 | 0.620 |
Why?
| | Pleural Diseases | 2 | 2016 | 15 | 0.620 |
Why?
| | Pulmonary Medicine | 2 | 2015 | 15 | 0.620 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2019 | 28 | 0.610 |
Why?
| | Pleura | 2 | 2015 | 12 | 0.610 |
Why?
| | Ultrasonography | 2 | 2017 | 434 | 0.590 |
Why?
| | Diagnosis, Differential | 6 | 2022 | 1029 | 0.590 |
Why?
| | Time-to-Treatment | 1 | 2019 | 73 | 0.590 |
Why?
| | Hypotension | 1 | 2019 | 63 | 0.580 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2018 | 11 | 0.580 |
Why?
| | Respiratory Insufficiency | 3 | 2016 | 117 | 0.580 |
Why?
| | Sclerosing Solutions | 1 | 2017 | 15 | 0.560 |
Why?
| | Granuloma, Foreign-Body | 1 | 2017 | 4 | 0.560 |
Why?
| | Bronchial Diseases | 1 | 2017 | 8 | 0.560 |
Why?
| | Myofibroblasts | 1 | 2018 | 49 | 0.560 |
Why?
| | Confusion | 1 | 2017 | 20 | 0.550 |
Why?
| | Foreign-Body Migration | 1 | 2017 | 32 | 0.550 |
Why?
| | Cryptococcosis | 1 | 2017 | 19 | 0.540 |
Why?
| | Middle Cerebral Artery | 1 | 2017 | 34 | 0.540 |
Why?
| | Ultrasonography, Interventional | 2 | 2015 | 137 | 0.540 |
Why?
| | Shock, Cardiogenic | 1 | 2017 | 25 | 0.540 |
Why?
| | Critical Illness | 5 | 2020 | 302 | 0.540 |
Why?
| | Mitral Valve | 1 | 2017 | 50 | 0.540 |
Why?
| | Referral and Consultation | 1 | 2019 | 287 | 0.540 |
Why?
| | Catheterization | 1 | 2017 | 102 | 0.540 |
Why?
| | Endocarditis, Bacterial | 1 | 2017 | 41 | 0.530 |
Why?
| | Tracheal Neoplasms | 1 | 2016 | 8 | 0.520 |
Why?
| | Pyrethrins | 1 | 2016 | 4 | 0.520 |
Why?
| | Flea Infestations | 1 | 2016 | 4 | 0.520 |
Why?
| | Granular Cell Tumor | 1 | 2016 | 6 | 0.520 |
Why?
| | Insecticides | 1 | 2016 | 13 | 0.520 |
Why?
| | Pulmonary Eosinophilia | 1 | 2016 | 7 | 0.520 |
Why?
| | Midodrine | 1 | 2016 | 6 | 0.520 |
Why?
| | Pulmonary Aspergillosis | 1 | 2016 | 5 | 0.520 |
Why?
| | Lymphoma | 1 | 2017 | 66 | 0.510 |
Why?
| | Superior Vena Cava Syndrome | 1 | 2015 | 11 | 0.490 |
Why?
| | Cytodiagnosis | 1 | 2015 | 41 | 0.490 |
Why?
| | Treatment Outcome | 9 | 2018 | 5265 | 0.490 |
Why?
| | Vascular Access Devices | 1 | 2015 | 22 | 0.490 |
Why?
| | Mediastinal Neoplasms | 1 | 2015 | 16 | 0.490 |
Why?
| | Peptic Ulcer | 1 | 2015 | 14 | 0.490 |
Why?
| | Osteochondrodysplasias | 1 | 2015 | 12 | 0.480 |
Why?
| | Tracheal Diseases | 1 | 2015 | 12 | 0.480 |
Why?
| | Gastrointestinal Agents | 1 | 2015 | 35 | 0.480 |
Why?
| | Critical Care | 1 | 2017 | 214 | 0.480 |
Why?
| | Leukemia, Plasma Cell | 1 | 2015 | 32 | 0.470 |
Why?
| | Hemorrhage | 1 | 2016 | 195 | 0.470 |
Why?
| | Trachea | 1 | 2015 | 53 | 0.460 |
Why?
| | Adrenal Glands | 1 | 2014 | 39 | 0.460 |
Why?
| | Magnesium | 1 | 2014 | 36 | 0.440 |
Why?
| | Myasthenia Gravis | 1 | 2014 | 17 | 0.440 |
Why?
| | Plasma Cells | 1 | 2015 | 220 | 0.430 |
Why?
| | Registries | 1 | 2017 | 565 | 0.430 |
Why?
| | Tomography, X-Ray Computed | 4 | 2025 | 1163 | 0.430 |
Why?
| | Stomach Neoplasms | 1 | 2017 | 187 | 0.420 |
Why?
| | Cisplatin | 1 | 2015 | 283 | 0.420 |
Why?
| | Deglutition Disorders | 1 | 2014 | 77 | 0.410 |
Why?
| | Myocardial Infarction | 1 | 2017 | 402 | 0.410 |
Why?
| | Ovarian Neoplasms | 1 | 2017 | 449 | 0.400 |
Why?
| | Smoking | 1 | 2016 | 506 | 0.400 |
Why?
| | Thrombosis | 1 | 2015 | 250 | 0.390 |
Why?
| | Neoplasms | 1 | 2021 | 1248 | 0.370 |
Why?
| | Internship and Residency | 1 | 2015 | 443 | 0.330 |
Why?
| | Endosonography | 3 | 2023 | 94 | 0.320 |
Why?
| | Breast Neoplasms | 1 | 2017 | 1198 | 0.280 |
Why?
| | Sepsis | 2 | 2023 | 225 | 0.280 |
Why?
| | Arterial Pressure | 2 | 2018 | 45 | 0.280 |
Why?
| | Organ Dysfunction Scores | 2 | 2017 | 18 | 0.280 |
Why?
| | Antineoplastic Agents | 1 | 2015 | 1165 | 0.270 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 373 | 0.260 |
Why?
| | Rare Diseases | 2 | 2018 | 43 | 0.260 |
Why?
| | Vancomycin | 2 | 2017 | 78 | 0.260 |
Why?
| | Incidence | 3 | 2019 | 1027 | 0.250 |
Why?
| | Drug Therapy, Combination | 2 | 2018 | 387 | 0.250 |
Why?
| | Predictive Value of Tests | 2 | 2021 | 924 | 0.250 |
Why?
| | Respiration, Artificial | 2 | 2020 | 298 | 0.250 |
Why?
| | Aged, 80 and over | 3 | 2017 | 3233 | 0.240 |
Why?
| | Neoplasm Staging | 2 | 2019 | 738 | 0.230 |
Why?
| | Acute Disease | 2 | 2016 | 374 | 0.230 |
Why?
| | Lymph Nodes | 2 | 2017 | 256 | 0.220 |
Why?
| | Ferritins | 2 | 2025 | 30 | 0.220 |
Why?
| | Prospective Studies | 3 | 2025 | 2378 | 0.210 |
Why?
| | Sputum | 1 | 2023 | 65 | 0.210 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2023 | 32 | 0.210 |
Why?
| | Multiple Pulmonary Nodules | 1 | 2022 | 11 | 0.200 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2022 | 5 | 0.200 |
Why?
| | Dizziness | 1 | 2022 | 13 | 0.200 |
Why?
| | Adenocarcinoma | 2 | 2017 | 396 | 0.190 |
Why?
| | Steroids | 1 | 2021 | 57 | 0.170 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2019 | 27 | 0.160 |
Why?
| | Faculty | 1 | 2020 | 71 | 0.160 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 1601 | 0.160 |
Why?
| | Echocardiography, Doppler | 1 | 2019 | 54 | 0.160 |
Why?
| | Lost to Follow-Up | 1 | 2019 | 10 | 0.160 |
Why?
| | Oncology Service, Hospital | 1 | 2019 | 14 | 0.160 |
Why?
| | Cocaine | 1 | 2019 | 183 | 0.150 |
Why?
| | Pulmonary Artery | 1 | 2019 | 153 | 0.150 |
Why?
| | Social Media | 1 | 2020 | 99 | 0.150 |
Why?
| | Hypertension, Pulmonary | 1 | 2019 | 123 | 0.140 |
Why?
| | Communication | 1 | 2020 | 256 | 0.140 |
Why?
| | Students, Medical | 1 | 2020 | 157 | 0.140 |
Why?
| | Heart Ventricles | 1 | 2019 | 266 | 0.140 |
Why?
| | Cocaine-Related Disorders | 1 | 2019 | 208 | 0.140 |
Why?
| | Catheters, Indwelling | 1 | 2017 | 57 | 0.140 |
Why?
| | Academic Medical Centers | 1 | 2018 | 147 | 0.140 |
Why?
| | Sutures | 1 | 2017 | 42 | 0.140 |
Why?
| | Anti-Bacterial Agents | 3 | 2017 | 751 | 0.140 |
Why?
| | Lung Abscess | 1 | 2017 | 5 | 0.140 |
Why?
| | Drainage | 1 | 2017 | 79 | 0.140 |
Why?
| | Administration, Intravenous | 1 | 2017 | 70 | 0.140 |
Why?
| | Serratia Infections | 1 | 2017 | 8 | 0.140 |
Why?
| | Etomidate | 1 | 2016 | 5 | 0.140 |
Why?
| | Esophagectomy | 1 | 2017 | 36 | 0.140 |
Why?
| | Young Adult | 2 | 2017 | 4075 | 0.130 |
Why?
| | Bronchial Fistula | 1 | 2016 | 4 | 0.130 |
Why?
| | Anesthetics, Intravenous | 1 | 2016 | 22 | 0.130 |
Why?
| | Device Removal | 1 | 2017 | 85 | 0.130 |
Why?
| | Bronchi | 1 | 2017 | 43 | 0.130 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2016 | 21 | 0.130 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2016 | 12 | 0.130 |
Why?
| | Prostheses and Implants | 1 | 2016 | 55 | 0.130 |
Why?
| | Fatal Outcome | 1 | 2017 | 197 | 0.130 |
Why?
| | Prosthesis Implantation | 1 | 2016 | 47 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2019 | 305 | 0.130 |
Why?
| | United States | 2 | 2017 | 5005 | 0.130 |
Why?
| | Penicillanic Acid | 1 | 2016 | 20 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 462 | 0.130 |
Why?
| | Airway Obstruction | 1 | 2016 | 47 | 0.130 |
Why?
| | Cephalosporins | 1 | 2016 | 39 | 0.130 |
Why?
| | Esophageal Neoplasms | 1 | 2017 | 105 | 0.130 |
Why?
| | Laser Therapy | 1 | 2016 | 83 | 0.120 |
Why?
| | Recurrence | 1 | 2017 | 657 | 0.120 |
Why?
| | Cost Savings | 1 | 2015 | 58 | 0.120 |
Why?
| | Inservice Training | 1 | 2015 | 34 | 0.120 |
Why?
| | Catheters | 1 | 2015 | 31 | 0.120 |
Why?
| | Disease Management | 1 | 2017 | 179 | 0.120 |
Why?
| | Odds Ratio | 1 | 2017 | 550 | 0.120 |
Why?
| | Pneumothorax | 1 | 2015 | 21 | 0.120 |
Why?
| | Electrocardiography | 1 | 2017 | 266 | 0.120 |
Why?
| | Coronary Angiography | 1 | 2017 | 360 | 0.120 |
Why?
| | Drug Utilization | 1 | 2015 | 79 | 0.120 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 269 | 0.120 |
Why?
| | Hospital Mortality | 1 | 2017 | 411 | 0.110 |
Why?
| | Tissue Plasminogen Activator | 1 | 2015 | 110 | 0.110 |
Why?
| | Survival Rate | 1 | 2017 | 906 | 0.110 |
Why?
| | Cost-Benefit Analysis | 1 | 2015 | 263 | 0.110 |
Why?
| | Echocardiography | 1 | 2017 | 398 | 0.110 |
Why?
| | Staphylococcus aureus | 1 | 2017 | 321 | 0.110 |
Why?
| | Infusions, Intravenous | 1 | 2014 | 212 | 0.110 |
Why?
| | Blood Pressure | 1 | 2016 | 525 | 0.110 |
Why?
| | Antifungal Agents | 1 | 2016 | 342 | 0.110 |
Why?
| | Blood Loss, Surgical | 1 | 2013 | 67 | 0.100 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2017 | 622 | 0.100 |
Why?
| | Age Factors | 1 | 2016 | 1118 | 0.100 |
Why?
| | Thoracostomy | 1 | 2012 | 11 | 0.100 |
Why?
| | Immunohistochemistry | 1 | 2015 | 955 | 0.100 |
Why?
| | Chest Tubes | 1 | 2012 | 21 | 0.100 |
Why?
| | Hospitalization | 1 | 2017 | 677 | 0.100 |
Why?
| | Acute Kidney Injury | 1 | 2016 | 302 | 0.100 |
Why?
| | Preoperative Care | 1 | 2013 | 170 | 0.100 |
Why?
| | Risk Assessment | 1 | 2016 | 1268 | 0.100 |
Why?
| | Cohort Studies | 1 | 2015 | 1451 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2017 | 1030 | 0.080 |
Why?
| | Cronobacter sakazakii | 1 | 2009 | 5 | 0.080 |
Why?
| | Enterobacteriaceae Infections | 1 | 2009 | 16 | 0.080 |
Why?
| | Osteomyelitis | 1 | 2009 | 125 | 0.070 |
Why?
| | Fluoroscopy | 1 | 2025 | 48 | 0.060 |
Why?
| | Adolescent | 1 | 2015 | 6453 | 0.060 |
Why?
| | Radiation Dosage | 1 | 2025 | 162 | 0.060 |
Why?
| | Polymyxin B | 1 | 2023 | 4 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2023 | 105 | 0.050 |
Why?
| | Dogs | 1 | 2022 | 185 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2019 | 2231 | 0.050 |
Why?
| | Research Design | 1 | 2023 | 348 | 0.050 |
Why?
| | Multiple Myeloma | 1 | 2015 | 2990 | 0.040 |
Why?
| | Systole | 1 | 2019 | 72 | 0.040 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2019 | 59 | 0.040 |
Why?
| | Education, Medical | 1 | 2020 | 109 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2019 | 223 | 0.040 |
Why?
| | Serratia marcescens | 1 | 2017 | 8 | 0.030 |
Why?
| | Arkansas | 2 | 2016 | 1974 | 0.030 |
Why?
| | Piperacillin | 1 | 2016 | 23 | 0.030 |
Why?
| | Prosthesis Failure | 1 | 2016 | 110 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2016 | 245 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 122 | 0.030 |
Why?
| | Erythrocyte Indices | 1 | 2013 | 7 | 0.030 |
Why?
| | Dilatation | 1 | 2013 | 26 | 0.030 |
Why?
| | Length of Stay | 1 | 2016 | 631 | 0.030 |
Why?
| | Patient Safety | 1 | 2013 | 102 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2013 | 1152 | 0.020 |
Why?
| | Prognosis | 1 | 2015 | 1974 | 0.020 |
Why?
| | Discitis | 1 | 2009 | 11 | 0.020 |
Why?
| | Animals | 1 | 2022 | 13063 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2009 | 1546 | 0.010 |
Why?
|
|
Meena's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|